Also known as: venous thromboembolic events, VTE
Venous thromboembolism encompasses deep vein thrombosis and pulmonary embolism, caused by abnormal clot formation in venous circulation. It is a major source of preventable morbidity and mortality.
Two phase 3 trials found upadacitinib 15 mg significantly improved facial and total repigmentation versus placebo at 48 weeks in nonsegmental vitiligo. The 614-patient studies also showed continued improvement over time and a safety profile consistent with prior use.
A study identified host-response plasma protein candidate biomarkers to predict venous thromboembolism risk after pleural mesothelioma surgery. The exploratory cohort included 18 patients.
A clinical study in Shock found that Nu.Q H3.1 and H3R8 Citrulline were significantly elevated in 674 trauma patients, especially those who developed VTE. The findings point to potential clinical utility for trauma care and support commercialization of Nu.Q NETs.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
The FDA has approved a once-monthly dosing schedule for subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) combined with lazertinib for first-line treatment of EGFR-mutated advanced NSCLC, based on PALOMA-2 trial data showing comparable efficacy to biweekly dosing.
The FDA approved a once-monthly dosing schedule for Rybrevant Faspro with Lazcluze for first-line treatment of EGFR-mutated advanced NSCLC, reducing clinic visits while maintaining safety and efficacy established with bi-weekly dosing.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07603700 |
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism |
NOT_YET_RECRUITING | |
| NCT07596264 |
Development and Validation of an Interpretable Machine Learning Model for Predicting Venous Thromboembolism（VTE）in Intensive Care Unit (ICU) Patients |
COMPLETED | |
| NCT07506473 |
Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial |
NOT_YET_RECRUITING | NA |
| NCT07399977 |
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism |
RECRUITING | NA |
| NCT07350499 |
Aspiration Thrombectomy Using the Symphony or Prodigy System |
RECRUITING | |
| NCT07303816 |
Statins to Prevent Cancer Associated Blood Clots |
NOT_YET_RECRUITING | PHASE4 |
| NCT07196020 |
Prediction of Venous Thrombosis During chemotherapy-the PINPOINT Study |
RECRUITING | |
| NCT06950697 |
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors |
RECRUITING | |
| NCT06765681 |
An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related |
ACTIVE_NOT_RECRUITING | |
| NCT06495996 |
The Protrieve PROTECTOR Study |
COMPLETED | NA |
